On-demand CME activities - Dermatology
 |
Strategies for Managing Cardiovascular Comorbidities in Psoriasis PatientsA CME-certified Expert Practice article posted on PsoriasisTx.com based on an interview with Kenneth B. Gordon, MD. In this Expert Practice, Dr. Kenneth Gordon discusses the relationship between psoriasis and cardiovascular comorbidities. The role of the dermatologist in the identification and management of cardiovascular comorbidities in patients with psoriasis is also addressed.
|
|
 |
Practical Strategies for Managing Patients Previously Treated With Efalizumab
In this Clinically Challenging Case posted to PsoriasisTx.com, a 64-year-old female patient presents to your virtual office with psoriasis on her feet. You—in consultation with Jeffrey Weinberg, MD of St. Luke’s-Roosevelt Hospital Center—are managing her care.
|
|
|
Updates on Long-Term Safety and Monitoring for Biologic Agents
A CME-certified Expert Practice article posted on PsoriasisTx.com based on an interview with Jeffrey M. Weinberg, MD. In this Expert Practice, Weinberg discusses new developments relating to the long-term safety of biologics used to treat psoriasis and provides an overview of the newest safety information for all biologics currently approved to treat psoriasis, as well as information from clinical trials regarding agents in development.
|
|
|
Highlights From the 67th Annual Meeting of the American Academy of Dermatology
A CME-certified Expert Practice article posted on PsoriasisTx.com based on an interview with Jeffrey M. Weinberg, MD. In this Expert Practice, Dr. Weinberg from St. Luke’s-Roosevelt Hospital Center in New York discusses some of the psoriasis-related highlights of the meeting.
|
|
 |
Improving Outcomes for Psoriasis Patients: Lessons from Clinical Practice
A CME-certified Biologic Bulletin on PsoriasisTx.com edited by Jeffrey J. Crowley, MD and Neil J. Korman, MD, PhD. This Biologic Bulletin examines how clinicians can utilize biologics to improve outcomes for their patients with psoriasis and uses a case-based approach to illustrate the clinical decisions involved in developing a treatment strategy for patients with moderate to severe psoriasis.
|
|
|
Comorbidities Associated With Psoriasis: Implications for Patient Management
In this Clinically Challenging Case posted to PsoriasisTx.com, a 46-year-old male patient with recently diagnosed psoriasis presents to your virtual office, and you—in consultation with Jennifer C. Cather, MD, of Baylor University Medical Center—are reassessing his treatment regimen.
|
|
|
Year-End Review on Biologic Agents for Psoriasis
A CME-certified Expert Practice article posted on PsoriasisTx.com based on an interview with Craig Leonardi, MD. In this Expert Practice, Dr. Leonardi helps put the year's events into perspective and to review how these changes may affect the practicing dermatologist and ultimately improve the care provided to patients with psoriasis.
|
|
 |
Exploring New Concepts in the Pathophysiology of Psoriasis: Implications for Clinical Advances
This interactive CME/CNE-certified activity features an update on the pathophysioloy of psoriasis and evolving clinical data on novel agents in clinical development.
|
|
|
The Intersection of Genetics, Immunology, and Pathophysiology in Psoriasis
A CME-certified Expert Practice article posted on PsoriasisTx.com based on an interview with Kenneth Gordon, MD. In this Expert Practice, Dr. Gordon discusses the current scientific understanding of the pathophysiology of psoriasis, focusing on the genetics, immunobiology, and signaling pathways. Significant attention is given to explaining the impact of T-helper 17 (Th17) cell–specific pathways in the development of psoriasis.
|
|
|
Guidelines for the Use of Biologics in the Treatment of Psoriasis: Practical Applications
A CME-certified Expert Practice article posted on PsoriasisTx.com based on an interview with Alan Menter, MD. The American Academy of Dermatology (AAD), in cooperation with a group of experts in the field of psoriasis, has recently released guidelines regarding the use of biologic therapies in patients with psoriasis and psoriatic arthritis. In this Expert Practice, Dr. Menter MD discusses the practical application of recommendations reviewed in the guidelines.
|
|
|
Strategies for Optimizing Management of Difficult-to-Treat Psoriasis
A 45-year-old male patient with a 15-year history of recalcitrant psoriasis presents to your virtual office, and you—in consultation with Jeffrey M. Weinberg, MD, of St. Luke's-Roosevelt Hospital Center and Beth Israel Medical Center in New York—are providing his care. Among the issues that arise over the course of this case are the safety and efficacy of combination therapy with biologics (eg, etanercept, efalizumab) and traditional systemic therapy agents (eg, methotrexate), monitoring for such adverse events as thrombocytopenia and hemolytic anemia, and the management of transient mild breakthrough and generalized inflammatory flare. This activity follows the progression of this case over several months, solicits your clinical input on key aspects of the case, and presents treatment recommendations provided from other clinicians who have "consulted" on this case.
|
|
|
Expert Insights on Biologic Agents and Psoriasis: Update From the American Academy of Dermatology (AAD) 66th Annual Meeting
The American Academy of Dermatology held its 66th Annual Meeting February 1–5, 2008 in San Antonio, Texas. A variety of posters that focused on biologic agents used to treat psoriasis were presented, covering such topics as new agents in development, long-term efficacy, and the use of biologic agents in difficult-to-treat patients. In addition, the meeting featured presentations on other topics relating to psoriasis, such as quality-of-life issues, pathophysiology, and comorbidities. This article features highlights from posters presented at the meeting along with insights by Dr. Kenneth B. Gordon on the clinical implications of these studies.
|
|
|
Examining Comorbidities Associated With Psoriasis
A CME-certified Expert Practice article posted on PsoriasisTx.com based on an interview with J. Mark Jackson, MD. In this Expert Practice, Dr. Jackson discusses what is currently known about the association of psoriasis and comorbidities related to cardiovascular disease.
|
|
|
Using Biologic Agents in Combination With Other Systemic Therapies in Psoriasis Patients
A CME-certified Expert Practice article posted on PsoriasisTx.com based on an interview with Jennifer C. Cather, MD. In this Expert Practice, Dr. Cather discusses the suitability of combining biologics with other types of psoriasis treatments, such as methotrexate, cyclosporine, or ultraviolet light
|
|
|
New Biologic Agents in Development for Psoriasis A CME-certified Expert Practice article posted on PsoriasisTx.com based on an interview with Gerald G. Krueger, MD. In this Expert Practice, Dr. Krueger discusses the mechanisms of action of these agents in development, as well as the clinical data reported to date.
|
|
 |
Evolution of the Treatment of Hand and Foot PsoriasisThis interactive CME/CNE-certified activity features an update on current treatment options for this difficult-to-treat condition together with case studies presented by national opinion leaders. | |
